← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Crinetics Pharmaceuticals, Inc.
San Diego, CA
$10,323,814
Total funding
9
Grants
Funding over time
peak $2.4M · FY2010–19$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,323,814 · 9
By mechanism
R44$8,983,964 · 4
R43$1,339,850 · 5
Investigators at Crinetics Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,448,103
R44 · FY2017 · DK
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,354,308
R44 · FY2018 · DK
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,162,633
R44 · FY2014 · DK
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$999,917
R44 · FY2013 · DK
Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias$998,741
R44 · FY2018 · DK
Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias$896,817
R44 · FY2019 · DK
Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control$783,766
R44 · FY2015 · HD
Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control$716,200
R44 · FY2016 · HD
Small molecule somatostatin agonists for neuropathic pain$326,121
R44 · FY2015 · NS
Discovery of novel small molecule drugs for Cushing's disease$299,510
R43 · FY2017 · DK
Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias$297,358
R44 · FY2017 · DK
Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control$296,283
R43 · FY2012 · HD
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$282,070
R43 · FY2011 · DK
Biosensors of GPCR Activation & Inhibition for Drug Discovery$237,895
R43 · FY2010 · GM
Peripheral administration of nonpeptide somatostatin agonists for ophthalmic dise$224,092
R43 · FY2014 · EY